Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Atea Pharmaceuticals, Inc. (AVIR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.22-5.38%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AVIR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Initiate clinical development of AT-587 for HEV treatment | It plans to start clinical work on a hepatitis E drug. | Intact | No AT-587 clinical start by end 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Hepatitis E (HEV) In July, Atea initiated a first-in-human Phase 1 clinical trial evaluating, AT-587, for the treatment of chronic HEV.” “Atea selected AT-587 as the lead product candidate and anticipates initiating a Phase 1 clinical program for AT-587 in mid-2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotech investment, not a proven earnings compounder. Its multi-year view is intact, but confidence is low because the business is loss-making and still depends on clinical and financial execution.
The valuation evidence is mixed: AVIR is described as cheap versus peers, yet it also carries a modest peer premium, and model confidence is low. The priced-in assessment is justified with no fragility flags, while the expectations gap is close to neutral.
Near term, results may remain uneven: AVIR had an earnings beat in August after misses in May and March, and the next report carries a meaningful risk of guidance cuts. Over the multi-year view, management is on track with C-BEYOND results and C-FORWARD enrollment, while cash and investments have declined and the stated runway extends through 2027.
The main clinical swing factor is C-FORWARD topline data, expected in early 2027, alongside continued delivery on the HCV program. The thesis also hinges on cash use staying consistent with the stated runway, guidance avoiding a cut, and whether supportive Healthcare sector results continue.
For the next 1 to 3 years, AVIR remains a high-risk, low-confidence clinical-stage thesis with meaningful trial progress but no established profitability. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain cash runway through 2027 with $301.8M cash | The company has $301.8 million cash to fund trials through 2027. | Intact | Cash falls below $300 million before end 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Research and Development Expenses: Research and development expenses decreased by $4.1 million from $32.3 million for the three months ended June 30, 2025 to $28.2 million for the three months ended June 30, 2026.” “First Quarter 2026 Financial Results Cash, Cash Equivalents and Marketable Securities : $256.0 million at March 31, 2026, compared to $301.8 million at December 31, 2025.” Delivery assessment Nov 4, 2026 |
Narrow operating losses from -$54.9M to -$48.0M quarterly | Operating losses are narrowing, showing some cost control. | Intact | Operating losses widen above -$54.9 million per quarter | Operating income: $-35.099M FY2026-Q2; GAAP. Published target: Operating loss <= -$48 million per quarter in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 12, 2026-35,099,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Research and Development Expenses: Research and development expenses decreased by $4.1 million from $32.3 million for the three months ended June 30, 2025 to $28.2 million for the three months ended June 30, 2026.” “First Quarter 2026 Financial Results Cash, Cash Equivalents and Marketable Securities : $256.0 million at March 31, 2026, compared to $301.8 million at December 31, 2025.” Delivery assessment Nov 4, 2026 |
Deliver topline results from global Phase 3 hepatitis C program | Atea aims to deliver Phase 3 hepatitis C trial results soon. | Improving | Phase 3 results delayed past 2026 or clearly negative | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “In July, Atea announced positive topline results from C-BEYOND, its Phase 3 trial conducted in North America evaluating the regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of chronic hepatitis C virus (HCV) infection compared to the regimen of sofosbuvir and velpatasvir (SOF/VEL; Epclusa ® ) in the modified intent-to-treat (mITT) population, achieving the trial’s primary endpoint.” “Following the recent topline readout for C-BEYOND and pending results from C-FORWARD, Atea anticipates submitting a new drug application (NDA) to the US Food & Drug Administration (FDA) in the second quarter of 2027.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.39 → $-1.48 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-25 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-26 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-27 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-28 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-29 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-30 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-07-31 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-01 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-02 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-03 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-04 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-05 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-06 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-07 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-08 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-09 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-10 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-11 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-12 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-13 | $-1.39 | $30,169,770 | 2 / 2 |
| 2026-08-14 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-15 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-16 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-17 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-18 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-19 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-20 | $-1.39 | $30,169,767 | 1 / 1 |
| 2026-08-21 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-22 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-23 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-24 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-25 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-26 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-27 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-28 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-29 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-30 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-08-31 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-01 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-02 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-03 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-04 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-05 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-06 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-07 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-08 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-09 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-10 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-11 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-12 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-13 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-14 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-15 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-16 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-17 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-18 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-19 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-20 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-21 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-22 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-23 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-24 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-25 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-26 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-27 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-28 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-29 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-09-30 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-01 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-02 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-03 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-04 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-05 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-06 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-07 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-08 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-09 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-10 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-11 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-12 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-13 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-14 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-15 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-16 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-17 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-18 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-19 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-20 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-21 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-22 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-23 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-24 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-25 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-26 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-27 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-28 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-29 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-30 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-10-31 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-11-01 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-11-02 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-11-03 | $-1.48 | $30,000,000 | 1 / 1 |
| 2026-11-04 | $-1.48 | $30,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.